Hoth Therapeutics Names Dr. Adam Friedman to Scientific Advisory Board

Tuesday, February 26, 2019 | Personnel/Company News , Atopic Dermatitis

Hoth Therapeutics, Inc. has named Adam Friedman, MD to the Company's Scientific Advisory Board. Hoth is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati.

Adam Friedman, MD, FAAD is Professor and Interim Chair of Dermatology and serves as Residency Program Director and Director of Translational Research in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences. Dr. Friedman completed his undergraduate training at the University of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine in New York. He completed his internship at New York Hospital Queens and returned to Einstein for his Dermatology residency, where he was appointed Chief Resident during his final year. Dr. Friedman joined the Einstein faculty after graduation and served as the Director of Dermatologic Research, Director of the Translational Research Fellowship, and the Associate Program Director.

Next Story


You must be logged in to leave a comment.